Cyclodextrins have been widely employed as solubility and dissolution modifying excipients invarious oral dosage forms. These dosage forms include conventional immediate release tablets, orallydisintegrating tablets, effervescent tablets, and modified release dosage forms including slow releaseor sustained release drug delivery systems [18–20]. Cyclodextrins are often preferred over organicsolvents as a means to enhance solubility and dissolution due to their safety and because they arewell tolerated. In addition, advances in genetic engineering, technology and process innovations ledto the production of αCD, βCD as well as γCD as pharmaceutical excipients on economically andcommercially acceptable scales. However, due to the relatively low solubility as well as nephrotoxicityof βCD, it is not suitable for parenteral administration. Consequently, more soluble and less toxiccyclodextrin derivatives have been developed, which include hydroxypropyl-β-cyclodextrin (HP-β-CD)and sulfobutylether-β-cyclodextrin (SBE-β-CD) [16]